RxDoctor Payments Data

June Mbae, MD

Pulmonary Disease · Meridian, MSNPI 1922531136

Payments from drug & device makers

$470in general payments, 2019–2025

Across 19 payments — averaging $24.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$123
  • Intuitive Surgical$100
  • AstraZeneca$58
  • GSK$44
  • Merck$33
  • Insmed, Inc.$32
  • plus $79 from 4 others

What the payments were for

  • Food & beverage$43793%
  • Education$327%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$470 in reported general payments places this provider in the 20th percentile of 101 pulmonary disease providers in Mississippi.

See all pulmonary disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$86,254
Medicare patients
238
Services billed
882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter144$115,070
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$22,410
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$17,677
Spiriva RespimatTiotropium Bromide27$17,105
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$14,306
Combivent RespimatIpratropium/Albuterol Sulfate20$9,461
Breo ElliptaFluticasone/Vilanterol14$8,653
EliquisApixaban12$6,534
SymbicortBudesonide/Formoterol Fumarate16$3,974
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$3,927
Albuterol Sulfate HfaAlbuterol Sulfate118$3,428
BreynaBudesonide/Formoterol Fumarate13$2,363
Ventolin HfaAlbuterol Sulfate38$2,094
Mycophenolate Mofetil13$1,720
Theophylline ErTheophylline Anhydrous14$1,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$44$141,399196 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$123$48,97780 claims
AstraZenecaBreztri Aerosphere, Symbicort$58$18,28038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 101 pulmonary disease providers in Mississippi.

Other pulmonary disease in Meridian

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →